Home MarketXLS
Dashboard MarketXLS
Screener MarketXLS
Options Profit Calculator MarketXLS
Stock Ranks MarketXLS
Spreadsheet Builder MarketXLS
Documentation MarketXLS
Logout MarketXLS

EVOK Stock Annual Income Statement. Download in Excel

Evoke Pharma Inc. logo

Evoke Pharma Inc.

Sector: Healthcare   

Industry: Drug Manufacturers - Specialty & Generic

4.50
 
USD
  
-0.06
  
(-1.32%)
Previous close: 4.56  Open: 4.58  Bid: 4.2  Ask: 4.79
52 week range    
3.54   
   17.40
Mkt Cap: 7 M  Avg Vol (90 Days): 390,089
Peers   
IRWD / 
ANIP / 
Last updated: Friday 22nd November 2024

Stock Rankings

53
MarketXLS Rank
80
Value
30
Technical
50
Quality
How are these ranks calculated?
Ad slot not ready
Search for a stock

Financials

EVOK Income Statement

Annual
Dec-14Dec-15Dec-16Dec-17Dec-18Dec-19Dec-20Dec-21Dec-22Dec-23
Basic EPS from continuing operations-6.24-3.24-2.62-2.33
Basic EPS total-9.84-5.52-6.24-3.24-2.62-2.33
Basic weighted shares outstanding502713.0540482.0778172.01 M1 M2 M2 M3 M3 M3 M
Cost of sales86712.0328118.0370394.0201879.0
Diluted EPS total-26.4-22.44-13.8-10.8-5.52-3.84-6.24-3.24-2.62-2.33
Diluted normalized net income/share-2.62-2.33
Diluted weighted shares outstanding501806.0540172.0778879.01 M1 M2 M2 M3 M3 M3 M
GainOnSaleOfSecurity10187.0
GeneralAndAdministrativeExpense3 M4 M4 M4 M4 M4 M6 M9 M10 M12 M
Gross operating profit-63692.01 M2 M5 M
Income before tax-13 M-12 M-11 M-12 M-8 M-7 M-13 M-8 M-7 M-8 M
Interest income-97647.0-303160.0-801721.06519.015213.028798.05672.08615.062007.0138596.0
InterestExpenseNonOperating107834.0-510526.0112994.0500050.0500000.0500000.0
MiscOtherSpecialCharges597615.0-1 M433392.0105130.0
Net income from total operations-13 M-12 M-11 M-12 M-8 M-7 M-13 M-9 M-8 M-8 M
NetIncomeCommonStockholders-13 M-12 M-11 M-12 M-8 M-7 M-13 M-9 M-8 M-8 M
NetIncomeContinuousOperations-13 M-12 M-11 M-12 M-8 M-7 M-13 M-9 M-8 M-8 M
NetNonOperatingInterestIncomeExpense-97647.0-303160.0-801721.06519.015213.028798.0-107322.0-491435.0-437993.0-361404.0
Normalized income-6 M-6 M
Operating income-13 M-12 M-11 M-11 M-8 M-7 M-13 M-8 M-8 M-7 M
Operating income before depreciation (EBITDA)-13 M-13 M-11 M-12 M-8 M-7 M-13 M-8 M-8 M-7 M
OperatingExpense-13 M-12 M-11 M-11 M-8 M-7 M13 M10 M10 M12 M
Other income net-10187.0-597615.01 M-433392.0-105130.0
OtherGandA3 M4 M4 M4 M4 M4 M6 M9 M10 M12 M
OtherOperatingExpenses-86712.0-328118.0-370394.0-201879.0
RentAndLandingFees3 M4 M4 M4 M4 M4 M
Research & development expense10 M8 M7 M7 M4 M3 M7 M590476.0300789.0181907.0
ResearchExpense10 M8 M7 M7 M4 M3 M7 M590476.0300789.0181907.0
SalariesAndWages-2 M-1 M2 M2 M1 M1 M
Selling Gen & administrative expense3 M4 M4 M4 M4 M4 M6 M9 M10 M12 M
SellingAndMarketingExpense4 M
SellingExpense4 M
Total Income available for interest expense (EBIT)-13 M-13 M-11 M-12 M-8 M-7 M-13 M-8 M-8 M-7 M
Total common shares outstanding511424.0600147.01 M1 M1 M2 M3 M3 M3 M8 M
Total net income-13 M-12 M-11 M-12 M-8 M-7 M-13 M-9 M-8 M-8 M
Total ordinary shares734836.0734836.0734836.0734836.0734836.0734836.0734836.0734836.0734836.0734836.0
Total revenues23020.02 M3 M5 M
TotalExpenses-13 M-12 M-11 M-11 M-8 M-7 M13 M10 M10 M13 M
TotalRevenue23020.02 M3 M5 M
Call: 1-877-778-8358
Ankur Mohan MarketXLS
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.

I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and templates.

MarketXLS is a complete Excel stock solution

Kevin Hsu

StockKevin.com

I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel

Lloyd Lenase

Option Day Trader

MarketXLS is a data junkie’s dream. It gives me the flexibility to mine for hidden treasures.

Dave

Swing trader since 2011

I like to access historical closing prices on a particular date. That makes tracking performance easy.

Patrick Cusatis, Ph.D., CFA

Associate Professor of Finance - Penn State University